FDA Approves Treatment for Mantle Cell Lymphoma in Adults
Calquence's approval
This term refers to any clear sign or indication that the drug will eventually lead to a concrete clinical benefit. Instead of waiting to see how a drug impacts mortality or patient functioning, the FDA looks for any laboratory measurements, radiographic images, physical sign, or mental indication that the drug will lead to a positive clinical benefit over the course of its therapy. Calquence, for example, was approved based on its ability to shrink tumors, which is reasonably likely to extend the life of cancer patients.
